98 related articles for article (PubMed ID: 24778392)
1. Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine.
Force J; Saxena R; Schneider BP; Storniolo AM; Sledge GW; Chalasani N; Vuppalanchi R
J Clin Oncol; 2016 Jan; 34(3):e9-12. PubMed ID: 24778392
[No Abstract] [Full Text] [Related]
2. Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?
Lepelley M; Allouchery M; Long J; Boucherle D; Ranchoup Y; Le Marc'Hadour F; Villier C; Sturm N
Ann Hepatol; 2018 Oct; 17(6):1067-1071. PubMed ID: 30600283
[TBL] [Abstract][Full Text] [Related]
3. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1424):75-6. PubMed ID: 24043217
[No Abstract] [Full Text] [Related]
4. Ado-trastuzumab emtansine approved for advanced breast cancer.
Traynor K
Am J Health Syst Pharm; 2013 Apr; 70(7):562. PubMed ID: 23515502
[No Abstract] [Full Text] [Related]
5. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
[No Abstract] [Full Text] [Related]
6. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
7. Abnormal Corneal Lesions Induced by Trastuzumab Emtansine: An Antibody-Drug Conjugate for Breast Cancer.
Tsuda M; Takano Y; Shigeyasu C; Imoto S; Yamada M
Cornea; 2016 Oct; 35(10):1378-80. PubMed ID: 27149538
[TBL] [Abstract][Full Text] [Related]
8. Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer.
Bourdeanu L; Luu T
Clin J Oncol Nurs; 2013 Oct; 17(5):E58-62. PubMed ID: 24080060
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
Cho WC; Roukos DH
Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
[No Abstract] [Full Text] [Related]
10. Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.
Sibaud V; Niec RE; Schindler K; Busam KJ; Roché H; Modi S; Delord JP; Lacouture ME
Breast Cancer Res Treat; 2014 Jul; 146(2):451-6. PubMed ID: 24929675
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
Krop I; Winer EP
Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
[TBL] [Abstract][Full Text] [Related]
12. From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer.
Lianos GD; Roukos DH
Future Oncol; 2014 Feb; 10(2):145-8. PubMed ID: 24490597
[No Abstract] [Full Text] [Related]
13. Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage.
Kolarich AR; Reynolds BA; Heldermon CD
Acta Oncol; 2014 Oct; 53(10):1434-6. PubMed ID: 24834794
[No Abstract] [Full Text] [Related]
14. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
Diéras V; Harbeck N; Budd GT; Greenson JK; Guardino AE; Samant M; Chernyukhin N; Smitt MC; Krop IE
J Clin Oncol; 2014 Sep; 32(25):2750-7. PubMed ID: 25024070
[TBL] [Abstract][Full Text] [Related]
15. Corneal Changes in Trastuzumab Emtansine Treatment.
Kreps EO; Derveaux T; Denys H
Clin Breast Cancer; 2018 Aug; 18(4):e427-e429. PubMed ID: 29615304
[No Abstract] [Full Text] [Related]
16. T-DM1-related telangiectasias: a potential role in secondary bleeding events.
Sibaud V; Vigarios E; Combemale P; Lamant L; Lacouture ME; Lacaze JL; Dalenc F; Delord JP
Ann Oncol; 2015 Feb; 26(2):436-7. PubMed ID: 25403586
[No Abstract] [Full Text] [Related]
17. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.
Amiri-Kordestani L; Blumenthal GM; Xu QC; Zhang L; Tang SW; Ha L; Weinberg WC; Chi B; Candau-Chacon R; Hughes P; Russell AM; Miksinski SP; Chen XH; McGuinn WD; Palmby T; Schrieber SJ; Liu Q; Wang J; Song P; Mehrotra N; Skarupa L; Clouse K; Al-Hakim A; Sridhara R; Ibrahim A; Justice R; Pazdur R; Cortazar P
Clin Cancer Res; 2014 Sep; 20(17):4436-41. PubMed ID: 24879797
[TBL] [Abstract][Full Text] [Related]
18. Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review.
Kalsi R; Feigenberg S; Kwok Y; Tkaczuk K; Mehta M; Chumsri S
Clin Breast Cancer; 2015 Apr; 15(2):e163-6. PubMed ID: 25454740
[No Abstract] [Full Text] [Related]
19. T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice.
Michel LL; Bermejo JL; Gondos A; Marmé F; Schneeweiss A
Anticancer Res; 2015 Sep; 35(9):5085-90. PubMed ID: 26254411
[TBL] [Abstract][Full Text] [Related]
20. T-DM1-related carotenoderma and hand-foot syndrome.
Dholaria B; Srinivasan S
Lancet; 2015 Apr; 385(9977):1509-10. PubMed ID: 25933279
[No Abstract] [Full Text] [Related]
[Next] [New Search]
